This is important because improving SMN2 exon 7 inclusion is a goal of therapeutic strategies to treat patients with spinal muscular atrophy, which is caused by defects in the SMN1 gene resulting in SMN protein deficiency. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.